Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Collagen

This article was originally published in The Gray Sheet

Executive Summary

Collagen: Remaining shares of tissue adhesive and anti-adhesion product firm Cohesion Corp. not already owned are acquired for approximately $10 mil. Collagen, which had increased its stake in the privately held company to roughly 80% last year ("The Gray Sheet" June 3, 1996, p. 8), plans to make Cohesion the "centerpiece" of its Collagen Technologies R&D business -- which is scheduled to be spun off to Collagen shareholders as a separate company in 1998 ("The Gray Sheet" Nov. 3, In Brief). The new company, to be renamed Cohesion Technologies, plans to commence U.S. studies of its lead product candidate, the CoStasis "sprayable" hemostatic device (formerly CollaSeal), for multiple indications in 1998. The firm recently commenced European studies of the device for use in cardiothoracic indications...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts